Kinin B1 receptor antagonists containing α-methyl-L-phenylalanine: In vitro and in vivo antagonistic activities

Abstract

To protect from metabolism and to improve potency of the AcLys-[D- βNal7,Ile8]desArg9-bradykinin (BK) (R 715), we prepared and tested 3 analogues containing α-methyl-L-Phe ([(α)Me]Phe) in position 5: these are the AcLys-[((α)Me)Phe5,D-βNal7,Ile8]desArg9BK (R 892), Lys-Lys- [((α)Me)Phe5,D-βNal7,Ile8]desArg9BK (R 913), and AcLys-Lys- [((α)Me)Phe5,D-βNal7,Ile8]desArg9BK (R 914). The new compounds were tested against the contractile effect induced by desArg9BK on 2 B1 receptor bioassays, the human umbilical vein, and the rabbit aorta. Their antagonistic activities were compared with those of the early prototypes (Lys- [Leu8]desArg9BK and [Leu8]desArg9BK) and with other recently described peptide antagonists. The 3 ((α)Me)Phe analogues showed high antagonistic potencies (pA2) at both the human (8.8, 7.7, and 8.7, respectively) and rabbit (8.6, 7.8, and 8.6, respectively) B1 receptors. No antagonistic effects (pA2<5) were observed on the B2 receptors that mediate the contractile effects of BK on the human umbilical vein, the rabbit jugular vein, and the guinea pig ileum. Moreover, these new B1 antagonists were found to be resistant to in vitro degradation by purified angiotensin- converting enzyme from rabbit lung. The N(α)-acetylated forms, R 892 and R 914, were resistant to aminopeptidases from human plasma. In vivo antagonistic potencies (ID50) of B1 receptor antagonists were evaluated in anesthetized lipopolysaccharide-treated (for B1 receptor) and nontreated (for B2 receptor) rabbits against the hypotensive effects of exogenous desArg9BK and BK. R 892 efficiently inhibited (ID50 2.8 nmol/kg IV) hypotension induced by desArg9BK without affecting that evoked by BK (ID50 >600 nmol/kg IV). Conversely, the peptide antagonists Lys-Lys- [Hyp3,Igl5,D-Igl7,Oic8]desArg9BK (B 9858) and DArg-[Hyp3,Thi5,D- Tic7,Oic8] desArg9BK (S 0765) showed dual B1/B2 receptor antagonism in vitro and in vivo. It is concluded that R 892 and congeners provide selective, highly potent, and metabolically stable B1 kinin receptor antagonists that can be useful for the assessment of the physiological and pathological roles of kinin B1 receptors.